Nephroprotector effects of calcium antagonists;Effets nephroprotecteurs des antagonistes calciques

Presse Medicale

Volumn 28, Issue 30, 1999, Pages 1667-1670

  Deray, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CALCIUM ANTAGONIST; CYCLOSPORIN; DILTIAZEM; LISINOPRIL; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT;

BLOOD PRESSURE; CELL PROTECTION; DIABETIC NEPHROPATHY; HEMODYNAMICS; HUMAN; HYDROSTATIC PRESSURE; KIDNEY TRANSPLANTATION; PROTEINURIA; REVIEW; ARTICLE; CHRONIC KIDNEY FAILURE; HYPERTENSION; RENOVASCULAR HYPERTENSION;

CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC;

EID: 0033539358     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Burke TJ, Arnold PE, Gordon JA et al. Protective effect of intrarenal calcium membrane blockers before or after renal ischemia. J Clin Invest 1984 ; 74:1830-41.
2. Chintala MS, Jandhyala BS. Renal failure in haemorrhagic shock in dogs : salutary effects of the calcium entry blocker felodipine. Naunyn-Schmiedeberg's Arch Pharmacol 1990 ; 341:357-63.
3. Jacinto SM, Jandhyala BS. Evaluation of the effects of felodipine, verapamil and hydralazine on the survival rate of rats subjected to lethal effects of oxygen free radicals. Naunyn-Schmiedeberg's Arch Pharmacol 1992 ; 346:457-61.
4. Rose UM, Bindels RJM, Vis AM, Jansen WCM, Vances CH. The effects of L-type Ca2+ channel blockers on anoxia-induced increases in intracellular Ca2+ concentration in rabbit proximal tubule cells inprimary culture. Pfluger's Arch 1993 ; 423:378-86.
5. Bagnis C, Deray G, Dubois M, Jacquiaud C, Bitker MO, Jacobs C. Prevention of acute cyclosporin nephrotoxicity by verapamil and atrial natriuretic factor in the rat Nephrol Dial Transplant 1994 ; 9:1143-8.
6. Dieperink H, Hansen HV, Kem M, Leyssac PP, Starklin TH, Kem PE. Antagonist capacity of felodipine on cyclosporin A nephrotoxicity in the rat. Nephrol Dial Transplant 1992 ; 7:1124-9.
7. Dawidson I, Rooth P, Lu C et al. Verapamil improves the out-come after cadaver renal transplantation. J Am Soc Nephrol 1991 ; 2:983-90.
8. Neumayer HH, Wagner K. Prevention of delayed graft function after cadaver kidney transplants by diltiazem : outcome of two prospective, randomized clinical trials. Cardiovasc Pharmacol 1987 ; 10(suppl 10):S170-7.
9. Nyberg C, Haljamae U, Herlitz H, Norden C, Blohme I. Early renal graft function in recipients treated with the calcium channel blocker felodipine. Scand J Urol Neprol 1993 ; 28:17-20.
10. Sorensen SS, Skovbon H, Eiskjaer H et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol Dial Transplant 1992 ; 7:69-78.
11. Pedersen EB, Madsen JK, Sorensen SS, Zachariae H. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies. Kidney Int 1996 ; 49(suppl. 55):S94-6.
12. Neumayer HL, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney Int 1992 (S36) 41:S87-93.
13. Pesavento T, Jones P, Julian B, Cuetis J. Amlodipine increases cyclosporin levels in hypertensive renal transplant patients. Results of a prospective study. J Am Soc Nephrol 1996 ; 7:831-5.
14. Van Der Schaaf M, Hene RJ, Floor M, Blankestfin PJ, Koomans HA. Hypertension after renal transplantation calcium channel or converting enzyme blockade. Hypertension 1995 ; 25:77-81.
15. Walker GW, Neaton JD, Cutler JA, Neuwirth R, Cohen JD for the MRFIT Research Group. Renal function change in hypertensive members of the multiple risk factor intervention trial. Racial and treatment effects. JAMA 1992 ; 268:3085-91.
16. Brazy PC, Fitzwilliam JF. Progressive renal disease : role of race and antihypertensive medications. Kidney Int 1990 ; 17:1113-19.
17. Eliahou HE, Cohen D, Helberg B et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man. Am J Nephrol 1988 ; 8:285-90.
18. Zucchelli P, Zuccala A, Borghi M et al. Long-term comparison between captopril and felodipine in the progression of renal insufficiency. Kidney Int 1992 ; 42:452-8.
19. Siewert-Delle A, Ljungman S, Hardford M, Wikstrand J. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with ß-blockade.
20. Mimran A, Insua A, Ribstein J et al. Contrasting effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertension 1988 ; 6:919-23.
21. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990 ; 112:701-2.
22. Bakris GL, Barnhill BW, Sadler R Treatment of arterial hypertension in diabetic humans : Importance of therapeutic selection. Kidney Int 1992 ; 41:912-19.
23. Slataper R, Vicknair N, Sadler R, Bakris G. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993 ; 153:973-80.
24. Bakris GL, Copley B, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996 ; 520:1641-50.
25. Saruta T, Kanno Y, Hayashi K, Konishi K. Antihypertensive agents and renal protection : calcium channel blockers. Kidney Int 1996 ; 49 (S55):S52-6.
26. Francischetti A, Ono H, Frohlich E. Renoprotective effects of felodipine and/or enalapril in spontaneously hypertensive rats with and without L-NAME. Hypertension 1998 ; 31:795-801.
27. Schlondroff D, Neuwirth R. Platelet activating factor and the kidney. Am J Phsiol 1986 ; 251:F1-11.
28. Lovett DH, Martin M, Burstein J. Interleukin-1 and the glomerular mesangium. IL-1 dependent stimulation of mesangial cell protein kinase activity. Kidney Int 1988 ; 34:26-35.